<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513981</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-NAG-2005-13</org_study_id>
    <secondary_id>CDR0000560133</secondary_id>
    <secondary_id>EU-20744</secondary_id>
    <secondary_id>EUDRACT-2005-001757-13</secondary_id>
    <nct_id>NCT00513981</nct_id>
  </id_info>
  <brief_title>High-Dose Methotrexate in Treating Young Patients With Solid Tumors</brief_title>
  <official_title>Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as high-dose methotrexate work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Chemoprotective drugs, such as leucovorin calcium, may protect normal cells from&#xD;
      the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of&#xD;
      high-dose methotrexate in treating patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated time to exposure to high-dose methotrexate when&#xD;
           administered as a continuous infusion at a dose of 6 g/m² per 24 hours.&#xD;
&#xD;
        -  To relate the methotrexate schedules investigated to the magnitude and duration of&#xD;
           changes in plasma homocysteine and methionine.&#xD;
&#xD;
        -  To relate evidence of the systemic effect of methotrexate through changes in plasma&#xD;
           homocysteine and methionine to any hepatic, neurological, or antiproliferative toxicity&#xD;
           observed in the study group.&#xD;
&#xD;
      OUTLINE: Patients receive a continuous infusion of high-dose methotrexate IV over 24, 30, 36,&#xD;
      or 42 hours depending on time of study entry. Beginning at hour 42 or 48, patients receive&#xD;
      leucovorin calcium IV every 6 hours for 3 days or until plasma methotrexate concentration is&#xD;
      &lt; 0.2 µM. Treatment repeats every 2 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study and analyzed for&#xD;
      pharmacodynamic effects on plasma homocysteine and methionine by gas chromatography/mass&#xD;
      spectrometry techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated infusion time for high-dose methotrexate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma biochemical evidence of the systemic effect of methotrexate in terms of changes in plasma homocysteine and methionine</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven malignancy, including but not limited to, any of the following:&#xD;
&#xD;
               -  Patients with MRI findings in keeping with a diffuse intrinsic pontine glioma&#xD;
                  will be eligible without histological confirmation of tumor type&#xD;
&#xD;
                    -  Patients with a diagnosis of diffuse intrinsic pontine glioma who are not&#xD;
                       eligible for the erlotinib hydrochloride phase I study (CCLG-NAG-2005-09)&#xD;
&#xD;
               -  Patients with relapsed ependymoma following the CCLG phase II study of&#xD;
                  intravenous etoposide (CCLG-CNS-2001-4) or prior to this are eligible at the&#xD;
                  discretion of the physician&#xD;
&#xD;
               -  Patients with relapsed osteogenic sarcoma, other soft tissue sarcomas, or other&#xD;
                  solid tumors may be suitable for this study at the discretion of the physician&#xD;
&#xD;
          -  Radiologically evaluable disease without bone marrow involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Lansky performance status (PS) 30-100% (for patients ≤ 12 years of age)&#xD;
&#xD;
          -  ECOG PS ≤ 2 (for patients ≥ 13 years of age)&#xD;
&#xD;
          -  Life expectancy ≥ 9 weeks&#xD;
&#xD;
          -  ANC &gt; 1,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN) for age&#xD;
&#xD;
          -  Serum total bilirubin normal&#xD;
&#xD;
          -  AST or ALT ≤ 2 times ULN&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 60 mL/min&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Poor medical risk because of nonmalignant systemic disease or uncontrolled infection&#xD;
&#xD;
          -  Concurrent malignancies at other sites&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Prophylactic trimethoprim-sulfamethoxazole must be stopped 1 week prior to&#xD;
             methotrexate administration&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Received chemotherapy or biologic therapy within the past 4 weeks&#xD;
&#xD;
          -  Received radiotherapy within the past 6 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy J. Estlin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Manchester Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PCE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

